Farmers & Merchants Investments Inc. Sells 237 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Farmers & Merchants Investments Inc. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 2.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,492 shares of the biopharmaceutical company’s stock after selling 237 shares during the period. Farmers & Merchants Investments Inc.’s holdings in Gilead Sciences were worth $688,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. PCA Investment Advisory Services Inc. acquired a new stake in Gilead Sciences in the 2nd quarter valued at approximately $25,000. OFI Invest Asset Management acquired a new stake in Gilead Sciences in the 3rd quarter valued at approximately $26,000. Tompkins Financial Corp grew its holdings in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the last quarter. Union Savings Bank acquired a new stake in Gilead Sciences in the 2nd quarter valued at approximately $29,000. Finally, Fortitude Family Office LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at approximately $29,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 1.1 %

Shares of GILD opened at $72.09 on Wednesday. The stock has a fifty day moving average price of $74.31 and a two-hundred day moving average price of $77.18. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a 52-week low of $71.37 and a 52-week high of $87.86. The company has a market cap of $89.76 billion, a price-to-earnings ratio of 16.02, a PEG ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter in the previous year, the firm posted $1.67 EPS. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post 7.07 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.27%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is presently 68.44%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the sale, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The disclosure for this sale can be found here. Insiders sold a total of 17,242 shares of company stock worth $1,423,646 over the last 90 days. 0.21% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Barclays lowered their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Cantor Fitzgerald decreased their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. Oppenheimer decreased their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, February 12th. Finally, Mizuho decreased their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $85.36.

Check Out Our Latest Stock Report on Gilead Sciences

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.